Phase 3 randomized COMMODORE 2 trial: Crovalimab versus eculizumab in patients with paroxysmal nocturnal hemoglobinuria naive to complement inhibition.
Roberta Demichelis-Gómez, Martin Höglund, Chatree Chai-Adisaksopha, Jun Ho Jang, Alexander Röth, Hongyan Tong, Anna Gaya, Naoshi Obara, Chattree Hantaweepant, Je-Hwan Lee, Teresita E Dumagay, Antonio Risitano, Jun-Ichi Nishimura, Sasha Sreckovic, Pontus Lundberg, Sammy Chebon, Simon Buatois, Leigh Beveridge, Richard J Kelly, Ponlapat Rojnuckarin, Andres Brodsky, Zenghua Lin, Brittany Gentile, Fernando Silva, Bing Han, Jing Sun, Xiaoqin Wang, Guangsheng He
American journal of hematology 2024;99(9):1768-1777